Suggested remit: To appraise the clinical and cost effectiveness of daratumumab with bortezomib, lenalidomide and dexamethasone within its marketing authorisation for untreated multiple myeloma when stem cell transplant is unsuitable.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Process:
- STA Standard
- ID number:
- 3843
Provisional Schedule
- Committee meeting: 1:
- 03 December 2025
- Expected publication:
- 25 February 2026
Project Team
- Project lead
- Vonda Murray
Email enquiries
If you have any queries please email [email protected]
Stakeholders
- Companies sponsors
- Janssen (daratumumab)
- Others
- Department of Health and Social Care
- NHS England
- Heath Technology Wales
- Patient carer groups
- African Caribbean Leukaemia Trust
- Anthony Nolan
- Black Health Agency for Equality
- Blood Cancer UK
- Cancer Black Care
- Cancer52
- Helen Rollason Cancer Charity
- Independent Cancer Patients Voice
- Kevin Karawa Leukaemia Trust
- Leukaemia Cancer Society
- Leukaemia Care
- Leukaemia UK
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie
- Myeloma UK
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tenovus Cancer Care
- Professional groups
- Association of Cancer Physicians
- British Blood Transfusion Society
- British Committee for Standards in Haematology
- British Geriatrics Society
- British Institute of Radiology
- British Oncology Pharmacy Association
- British Psychosocial Oncology Society
- British Society for Haematology
- British Society of Interventional Radiology
- British Transplantation Society
- Cancer Research UK
- NHS Blood and Transplant
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- UK Clinical Pharmacy Association
- UK Myeloma Society
- UK Oncology Nursing Society
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Advanz Pharma (lenalidomide)
- Amarox (lenalidomide)
- Aspire Pharma (bortezomib)
- Aurobindo Pharma (bortezomib)
- Biocon Pharma (lenalidomide)
- Biotech Pharma (bortezomib)
- Bristol Myers Squibb (lenalidomide)
- Dr Reddy’s Laboratories (bortezomib)
- Grindeks Kalceks (lenalidomide)
- Mylan (lenalidomide)
- MSN laboratories Europe (bortezomib)
- Pfizer (bortezomib)
- Piramal Critical Care (lenalidomide)
- Ranbaxy (bortezomib, lenalidomide)
- Sandoz (bortezomib, lenalidomide)
- Sanofi (isatuximab)
- Teva UK (lenalidomide)
- Thornton & Ross (bortezomib, lenalidomide)
- Tillomed Laboratories (bortezomib)
- Zentiva (bortezomib)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Cochrane Haematological Malignancies Group
- Genomics England
- Institute of Cancer Research
- Leukaemia Busters
- MRC Clinical Trials Unit
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 13 May 2025 | Invitation to participate |
| 17 March 2025 - 14 April 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 3843 |
| 17 March 2025 | In progress. Scoping commencing |
| 04 November 2024 | Please note that following on from a request received from the company, the appraisal has been scheduled back into the work programme and it is now anticipated to begin in early mid-May 2025 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-July 2025. |
| 19 July 2023 | Suspended. Please note that following on from information received from the company, NICE has decided to suspend this appraisal from its current work programme. The timelines for this appraisal are to be aligned with the latest regulatory and UK launch expectations and further information regarding the scheduling of this appraisal will be available in due course. NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
| 16 June 2021 | Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course. |
For further information on our processes and methods, please see our CHTE processes and methods manual